Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Andrew J Menssen, BA, Ajay Khanna, Christopher A Miller, PhD, Gue Su Chang, PhD, Jin J Shao, Sridhar Nonavinkere Srivatsan, MS, Joshua Robinson, Michelle O'Laughlin, Catrina Fronick, BS, Robert Fulton, MS, Kimberly J Brendel, Sharon E Heath, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD, Daniel C. Link, MD, Meagan A. Jacoby, Eric Duncavage, MD, Timothy J Ley, MD, Matthew J. Walter, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140394

Published: 2020

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MDPhD, Gail J. Roboz, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Sangmin Lee, MD, Michael P. Rettig, PhD, Tae H. Han, PhD, Jeanmarie Guenot, PhD, Eric J. Feldman, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2018-99-111529

Published: 2018

Journal Articles

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Michael P. Rettig, PhD, Geoffrey L. Uy, MD, Asad Bashey, MD PhD, Steven Devine, Samantha Jaglowski, MDMPH, Abi Vainstein, MD, Ella Sorani, PhD, Hemda Chen, PharmD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 118.

https://doi.org/10.1182/blood-2018-99-109701

Published: 2018

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Michael Slade, MDMS, Ramzi Abboud, MD BS, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4575.

https://doi.org/10.1182/blood.V130.Suppl_1.4575.4575

Published: 2017

Journal Articles

Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential

Blood (2017) 130 (Supplement 1): 469.

https://doi.org/10.1182/blood.V130.Suppl_1.469.469

Published: 2017

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant

Meagan Jacoby, MD PhD, Eric J. Duncavage, MD, Gue Su Chang, PhD, Christopher A Miller, PhD, Jin Shao, Kevin Elliot, Joshua Robinson, Robert S Fulton, Catrina Fronick, Michelle O'Laughlin, Daniel C. Link, MD, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Timothy James J Ley, MD, Timothy Aaron Graubert, MD, Matthew J. Walter, MD

Blood (2017) 130 (Supplement 1): 4232.

https://doi.org/10.1182/blood.V130.Suppl_1.4232.4232

Published: 2017

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Rizwan Romee, MD, Sarah Cooley, MD, Melissa Berrien-Elliott, PhD, Peter Westervelt, MDPhD, Michael R Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John F DiPersio, MD PhD, Amanda F. Cashen, MD, Emily K Jeng, Amy Rock, Hing C Wong, PhD, Todd A. Fehniger, MDPhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 274.

https://doi.org/10.1182/blood.V130.Suppl_1.274.274

Published: 2017

Journal Articles

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Eric Huselton, MD, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Meagan Jacoby, MD PhD, Iskra Pusic, MD, Rizwan Romee, MD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD

Blood (2017) 130 (Supplement 1): 5067.

https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067

Published: 2017

Journal Articles

Downregulation of MHC Class II in Relapsed AML Cells after Allogeneic Transplantation

Blood (2017) 130 (Supplement 1): 2678.

https://doi.org/10.1182/blood.V130.Suppl_1.2678.2678

Published: 2017

NARROW

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS

Downregulation of MHC Class II in Relapsed AML Cells after Allogeneic Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only